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Abstract
Introduction: Transfusion treatment (TT) is necessary in patients with gastrointestinal bleeding (GIB) for lost 
blood substitution. This study was aimed at assessing the changes in haematological parameters (hemoglo-
bin, hematocrit, red blood cell count, white cell count, platelet count and prothrombin time) before and after 
TT in anaemic patients with GIB in order to analyse the effect of this treatment. 
Methods: There have been included 293 patients with GIB (the average age was 57.3, ranged from 18-89 
years) who were treated with TT at the Internal Clinic at the University Clinical Center Prishtina during one 
year period. Data for applied blood product and results of the coagulation screen (PT) were collected from 
the Kosovo’s Blood Transfusion Center (KBTC). 
Results: TT has been carried out in 404 episodes, with 714 units of concentrated red blood cells (78.6%), 
189 units of fresh frozen plasma (20.8%) and concentrated platelets (0.6%), with an average dose 3.1 for 
transfunded patients. Average values of Hb before and after TT were 71.8 g/L and 81.4 g/L, respectively; 
while the average values of hematocrite before and after TT were 22.9% and 25.6%, respectively. The aver-
age erythrocytes count before TT was 2.6 respectively after treatment 2.8(p<0.0001). The PT was carried out 
in the 43% of patients with GIB before treatment with FFP, but after that only in 2% of cases.
Conclusions: Having in mind difficult clinical and unsustainable situation in patients with gastrointestinal 
bleeding, the Transfusion Treatment resulted in the considerable improvement of the specific blood indica-
tors. © 2012 All rights reserved
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Introduction
Transfusion treatment (TT) is a basic ele-
ment in the treatment of acute, persisting 
gastrointestinal bleeding, which may pres-
ent a high mortality rate ranging from 5 to 
10% according to the various series (1, 2).
One of the main aims when treating patients 
with upper or lower gastrointestinal bleeding is 
to treat hypovolemia resulting from loss of blood 
(3, 4). The early management of GIB is based on 
resuscitative measures of fluid infusion or blood 
transfusion to reverse the direct consequences 
of bleeding; prevention of end-organ damage in-
duced by the bleeding, such as hypoxia (5). The 
amount of transfusion of red blood cells and 
blood products must be individualized, depend-
ing on the characteristics of each specific case 
(speed of blood loss, state of cardiovascular re-
serve, other organ or vital system pathology, in-
jury causing bleeding, re-bleeding etc.) (6, 7).
According to the guidelines, in the absence of 
risk factors and symptoms, the patients should 
not be given a blood transfusion regardless of 
their haemoglobin level. However, few studies 
have attempted to validate appropriateness of 
blood transfusion according to these criteria (8).
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At the present time it is very hard to establish the 
appropriateness of RBC transfusion in GIB (9). 
Assessing whether a patient is actively bleeding or 
not at the time of transfusion is sometimes difficult 
and the haemoglobin value alone at presentation 
may not accurately reflect blood loss and or help 
decision-making about the need for RBC transfu-
sion (10). An Hb of >10g/dL has been used as a cut 
off for inappropriate transfusion in those patients 
who did not present with signs or symptoms of 
shock, as per BSG guidelines (11). RBC transfusion 
is not indicated in haemodynamically stable pa-
tients where no haemoglobin value is available (1). 
Transfusion in those who are haemodynamically 
unstable at presentation with acute bleeding is re-
garded as appropriate (12). For patients who have 
stopped bleeding but are regarded as being at high 
risk of re-bleeding or death, a top-up transfusion to 
the haemoglobin of 10g/dL is reasonable (13-15). 
Coagulopathy (defined as an international normal-
ized ratio of prothrombin time >1.5) or thrombocy-
topenia (<50,000 platelets/μl) should be treated us-
ing fresh frozen plasma or platelets, respectively (4).
Also laboratory investigations: full blood count, 
urea and electrolytes, liver function tests and coag-
ulation screen should be measured at presentation 
with acute GIB for transfusion data (16). The initial 
haematocrit on admission is best interpreted when 
a recent prior baseline haematocrit is available for 
comparison. Serial haematocrits are helpful to 
assess the severity of the GIB but should be inte-
grated with the hemodynamic assessment because 
overhydration falsely depresses the haematocrit 
(5). Equilibration of hemoglobin concentration af-
ter transfusion has been estimated to take about 24 
hours, in persons who have not bled recently (17).
This study was aimed at assessing the changes in hae-
matological parameters (hemoglobin, hematocrit, 
red blood cell count, white cell count, platelet count 
and prothrombin time-PT) before and after treat-
ment with blood products in anaemic patients with 
GIB in order to analyse the effect of this treatment.
 
Methods
Study Subjects
The study included 293 patients with gastrointes-
tinal bleeding during one year period, who had 
been treated at the Internal Clinic in the Uni-
versity Clinical Center in Prishtina (UCC). The 
males were represented at 174 or 59.4% of cases 
with GIB compared to females with only 119 or 
40.6% of cases. Average age of patients was 57.3 
with SD 16.03 (range 18 to 89 years) (Table 1). 
Medical history record, diagnosis and treat-
ment of patients were performed at the Internal 
Clinic in UCC. The overall treatment of gas-
trointestinal bleeding included also TT. Dur-
ing bleeding episodes, treatment with transfu-
sion therapy was performed with concentrated 
red blood cells, fresh frozen plasma (FFP) and 
occasionally with concentrated platelets. 
The data were collected from protocols and medi-
cal history at Internal Clinic in the UCC in Pris-
tine. Also it was collected the data for prepared 
and applied units of concentrated red blood 
cells, fresh frozen plasma and concentrated 
platelets and results of the coagulation screen 
from the protocols of Kosovo’s Blood Transfu-
sion Center in Pristine (KBTC). In separate da-
tabase it was evidenced all collected data for the 
patients with GIB which had been treated by TT.
Patients with GIB treated only with FFP or 
concentrated platelets were excluded. Also 
there were excluded patients without he-
matological parameters before and after TT.
In addition, the type of used therapy (concen-
trated erythrocytes, frozen fresh plasma or con-
centrated platelets) and the type of GIB would 
be interesting to investigate, with the purpose 
to have greater experience in order that for 
the future to draw up a long-term strategy for 
more successful use of the transfusion therapy.
All the patients involved in this work are di-
vided into groups as per their age, gen-
Statistics parameters age (years)
Mean ± SD 57.3 ± 16.03
Sample size 293 
range 18-89
Median 59
Confidence Interval (CI) < 95% 55.8
Confidence Interval (CI) > 95% 58.85
Table 1.  Mean age of patients with GiB treated with blood 
products
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der, and localization of bleeding (the pa-
tients with upper GIB and the patients with 
lower GIB) which were treated with blood product.
In addition to this, it’s interesting the therapy use 
percentage studying with blood components and 
that as per the type of the product (concentrated 
erythrocytes, frozen fresh plasma and concen-
trated platelets), overall group of GIB. Also, it was 
calculated the mean transfused dose per patients 
for all applied blood products. All this is done with 
the purpose to have greater experience in order 
that for the future to draw up a long-term strategy 
for more successful use of the transfusion therapy.
Especially, there were analyzed hematological re-
sults (hemoglobin, hematocrit, red blood cell count, 
platelets count, and white blood cell count) before 
and after transfusion treatment with blood prod-
ucts (the measurements of hematological results 
were performed in blood counter Medonic 3200 
at the department of biochemistry in Diagnostic 
Center-University Clinical Center in Prishtina).
The patients who were treated with plasma have car-
ried out the haemostatic tests before and after the 
transfusion of fresh frozen plasma (Prothrombine 
time - PT was performed in Dia Med-x Haemo-
stasis), at the Department of haemostasis in BTC).
Also the patients were divided into groups on 
the basis of the hemoglobin value (after bleeding 
episodes): group I Hb level was <50 g/L, group II 
50-70 g/L, and group III with Hb >70 g/L, which 
have been treated with concentrated Erythrocytes. 
Statistical analysis
Statistical analysis was performed using IN-
STAT 2 statistical software system. A t test was 
used to calculate the difference (p value) in the 
hematological parameters before and after trans-
fusion treatment in the patients with gastroin-
testinal bleeding. There were calculated average 
values, standard deviation, minimum values, 
maximum values, and median, for all hematologi-
cal parameters. For all blood products were cal-
culated average transfused dose/unit per patient.
Results 
Transfusion treatment with blood products 
it has been carried out in 293 patients with 
GIB, who received 908 units of blood products 
with mean transfused unit 3.1 for patient. TT 
is more often needed in upper GIB (783 units 
of blood products were used in treatment of 
234 or 79.9% patients), than in lower GIB (59 
patients received 125 blood product units). 
Mean transfused units of blood products in upper 
GIB was higher than in lower GIB (3.3 respectively 
2.1), Table 2. Upper GIB is more often recorded 
than lower GIB in all patients (males and females).
This treatment resulted in significant improve-
ment of blood specific indicators (Hemoglobin) 
after treatment with the concentrated red blood 
cells of patients with gastrointestinal bleeding. 
Mean values of Hemoglobin prior to transfusion 
were 71.8 g/L (with SD 19.2, minimal and maxi-
mal values 47-145); and after receiving transfu-
sions of concentrated erythrocytes was 81.35 g/L 
(with Standard Deviation 18.8 minimal and maxi-
mal value 47-130 g/L), with p <0.0001 (Table 3).
Blood products upper GIB N (%)
lower 
GIB N (%)
total 
GIB N (%)
concentrated 
erythrocytes unit 613 (78.3) 101 (80.8) 714 (78.6)
ffP unit 165 (21.1) 24 (19.2) 189 ( 20.8)
concentrated 
platelets unit 5 (0.6) 0 5 (0.6)
total units 783 (100) 125 (100) 908 (100)
total Patients 234 (79.9) 59 (20.1) 293 (100)
Patients-Male 134(72.8) 40(27.2) 174(100)
Patients-female 100(85) 19 (15) 119 (100)
Mean transfused 
unit/patient 3.3 2.1 3.1
Table 2.  transfusion treatment with blood products in pa-
tients with Gastro intestinal Bleeding
Statistics 
parameters
Hb g/l 
before
Hb g/l 
after
Mean (Ẋ) ± SD 71.9 ± 19.2 81.4 ± 18.8
Sample size 404 402
range 47-145 47-130
Median 70 81
Confidence Inter-
val (CI) < 95% 70.03 79.5
Confidence Inter-
val (CI) > 95% 73.7 83.2
p <0.0001
Table 3.  changes of Hemoglobin before and after transfu-
sion treatment in patients with Gastro intestinal Bleeding
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It was found a significant difference between 
the mean value of hematocrit before and after 
blood transfusion treatment in patients with GIB 
(22.9% respectively 25.6% with p<0.0001) Table 4.
The changes were evident in the values of red 
blood cells count before and after application of 
blood transfusion in GIB, where, the average val-
ues of red blood cells count were 2.65, and after 
the transfusion of this treatment the values rose 
in 2.867x1012/L with value p<0.0001 (Table 5).
Mean values of the white cell count before 
and after transfusion treatment have un-
dergone a slight decrease (11.21 respec-
tively 10.8x109/L) value p<0.001(Table 6).
Blood component therapy has resulted in improve-
ment of the situation, causing increased platelet 
count. Mean values of the platelet count before 
blood transfusion were 221.99 (SD 109.72; minimal 
and maximal value 24.0- 696.0) and after transfu-
sion were 230.42 (SD 108.1 with minimal and max-
imal value 38.0-631) and value p<0.001 (Table 7).
Only 6.8% of patients with GIB who were 
treated with concentrated red blood cells have 
hemoglobin values lower than 50 g/L, while 
the most of them (82.9%) have been treated 
when Hb values was above 50 g/L (Table 8).
Statistics 
parameters Htc % before Htc % after
Mean (Ẋ) ± SD 22.85 ± 5.4 25.61 ± 5.06
Sample size 404 402
range 10-45 10-38.6
Median 22.6 26.0
Confidence Inter-
val (CI) < 95% 22.3 25.1
Confidence Inter-
val (CI) > 95% 23.36 26.09
p <0.0001
Table 4.  changes of Hematocrit before and after transfu-
sion treatment in patients with Gastro intestinal Bleeding
Statistics 
parameters
white blood cell 
count x109/l before 
treatment
white blood cell 
count x109/l after 
treatment
Mean (Ẋ) ± SD 11.2 ± 9.04 10.8 ± 9.2
Sample size 404 402
range 0.9 – 20.5 1.8 – 4.8
Median 10.4 9.9
Confidence Inter-
val (CI) < 95% 10.3 11.7
Confidence Inter-
val (CI) > 95% 12.7 2.9
p<0.001
Patients no (293) 
%
20 
6.8%
189 
64.5%
84 
28.7%
Hb level g/l <50 g/L 50-70 g/l >70 g/L
no of episode 
(404) 30 174 200
Mean Hb (Ẋ) ± SD 42.6 ± 3.8 61 ± 5.6 83.5 ± 10.5
Statistics 
parameters
Platelet count 
x109/l before
treatment
Platelet count 
x109/l after
treatment
Mean ± SD 221.98 ± 109.7 230.4 ± 108.1
Sample size 404 402
range 24 – 696 38 - 631
Confidence Inter-
val (CI) < 95% 211.5 219.9
Confidence Inter-
val (CI) > 95% 232.5 240.99
p<0.001
Statistics 
parameters
red blood cell 
count x1012/l 
before treatment
red blood cell 
count x1012/l after 
treatment
Mean (Ẋ) ± SD 2.6 ± 1,1 2,9 ± 0.65
Sample size 404 402
range 1.06 - 20.5 1.1 – 4.8
Confidence Inter-
val (CI) < 95% 2.5 2.8
Confidence Inter-
val (CI) > 95% 2.75 2.9
p<0.0001
Table 6.  changes of white blood cells count before and 
after transfusion treatment in patients with Gastro intestinal 
Bleeding
Table 8.  application of concentrated red blood cells accord-
ing to the Hb values after bleeding episodes in patients with 
gastrointestinal bleeding 
Table 7.  changes of platelet count before and after transfu-
sion treatment in patients with Gastro intestinal Bleeding
Table 5.  changes of erythrocytes count before and after 
transfusion treatment in patients with Gastro intestinal Bleed-
ing
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In Table 9 have been presented 142 patients 
who were treated with plasma; only 61 of 
them were tested with PT, before treatment 
with Fresh Frozen Plasma, and after that only 
2.1% of cases were tested with PT. Fresh Fro-
zen Plasma are given to patients with GIB with 
average values of PT 71.2% before transfu-
sion and after transfusion this value rise to 72%.
Discussion 
GIB should be always appreciated as a major emer-
gency, regardless of the amount of blood lost and 
gravity of the clinical situation (18). Despite the 
progress that has been made in past years, in de-
termining the early lesion responsible for gastroin-
testinal bleeding (19), and in assessing the gravity 
of the situation accurately and to control its overall, 
mortality still remains high 10% (20) to 33% (11).
It is important to determine the exact amount 
of blood lost, which is difficult to do at the mo-
ment of meeting with the patient. The decline in 
hematocrit reflects the degree of blood loss after 
a delay of 24 hours or more from an acute GIB. 
Serial hematocrits are helpful to assess the sever-
ity of a GIB but should be integrated with the
hemodynamic assessment because overhydration 
falsely depresses the hematocrit (5, 21). Anemia 
is common in the critically ill patients with GIB 
and results in the frequent use of red blood cell 
(RBC) transfusions (22, 23). The initial hema-
tocrit on admission is best interpreted when a 
recent prior baseline hematocrit is available for 
comparison (5, 24). Other important laboratory 
parameters include the coagulation profile; rou-
tine serum chemistries, especially the blood urea 
nitrogen (BUN) and creatinine levels; and serum 
biochemical parameters of liver function, also 
are helpful to assess the severity of a GIB (5, 11).
Application of blood products should defi-
nitely be followed by the determination of he-
matological parameters before and after treat-
ment in order to know when to start and stop 
the transfusion treatment, considering that 
this treatment carries the possibility of ear-
ly and later transfusion complications (25).
The transfusion treatment with blood prod-
uct in patients with GIB has been carried out in 
404 transfusion episodes which resulted in im-
provement of specific blood indicators. Our data 
showed that the post-transfusion rise of hemoglo-
bin was about 10 g/L after the treatment with the 
concentrated erythrocytes in patients with GIB. 
The administration of 2 units of packed 
red cells elicited a 24-hour increase of 22.4 
+/- 6.8 g per L in haemoglobin concentra-
tion, data represented by Elizalde et al (26).
Hematocrit levels experienced similar changes 
after TT in patients with GIB. Post transfusion 
change of hematocrit was 2.8%. Data showed 
by Khilnani represented post transfusion he-
matocrit change up to 3% (3). But data showed 
by other authors represented more chang-
es in hematocrit value after TT (5.8%) (27).
The changes of value of red blood cell be-
fore and after TT were 0.2x1012/L in patients 
with GIB. Data offered by Ho CH presented 
more post transfusion change of red blood 
cell count up to 0.7 x 1012/L after the transfu-
sion treatment in patients with chronic anemia.
Serious situation in patients with GIB should 
evaluate not only with determining the red blood 
cell count, the hemoglobin and hematocrit level, 
but also through other indicators as the white cell 
no of cases 
treated 
with ffP
Statistical 
Parameters
of Pt
Before
treatment
after
treatment
upper GiB
no 116 
nr 51 2
% 44.0 1.7
Mean Pt 70.5 80
SD 24.6 7.1
Min 10 75
Max 120 85
lower GiB
no 26 
no 10 1
% 38.5 3.8
Mean Pt 74.8 56
SD 22.3 56
Min 40 56
Max 109 56
total
no 142 
nr 61 3
% 43.0 2.1
Mean Pt 71.2 72
SD 24.1 14.7
Min 10 56
Max 120 85
Table 9.  values of Pt before and after application of fresh 
frozen Plasma in patients with Gastro intestinal Bleeding
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count, platelet count, PT and other indicators (28). 
Transfusion treatment with blood products 
has resulted in declining the leucocytes aver-
age count after transfusion: (11,2 x 109/L before 
transfusion, i.e. 10,8x109/L after transfusion). 
Data showed by Barkun - International consen-
sus recommendations on the management of pa-
tients with GIB (5) represented that leukocytosis 
may be secondary to the stress of acute bleeding.
The transfusion treatment with blood products, 
erythrocytes and platelets, was not marked by 
significant increase of average values of platelet 
count before and after transfusion, where the post 
transfusion change was 7,5x109/L. Data from oth-
er authors indicate decrease in the platelet count 
with post transfusion change, -40x109/L (27).
There are many recommendations about Applica-
tion of concentrated red blood cells according to 
the Hb values: Hebert et al. (28) (Canada, 1993) 
with pretransfusion hemoglobin mean level 8.6 g/
dl; Vincent et al.(29) (Western Europe 1999) with 
pretransfusion hemoglobin mean level: 8.4; Rao 
et al.(30) (UK 1999) with pretransfusion hemo-
globin median level: 8.5 g/dl; Corwin et al.(31) 
(USA 2000 – 2001) with pretransfusion hemoglo-
bin mean level: 8.6; Walsh et al.(32) UK (Scotland 
2001) with pretransfusion hemoglobin median 
level: 7.8 g/dl; French et al. (33) (Australia and 
NewZealand 2001) with pretransfusion hemoglo-
bin median level: 8.2 g/dl; Vincent et al. (34) (West-
ern and Eastern Europe 2002) with pretransfusion 
hemoglobin median level: 8.2 g/dl; Westbrook et 
al.(35) (Australia and New Zealand 2008) with 
pretransfusion hemoglobin mean level: 7.7 g/dl.
Erythrocytes will be transfused when the pa-
tients had Hb less than 70 g/L with stable homo-
dynamic condition without bleeding; then when 
the patients had Hb below 80g/L with over 65 
years, with stable homodynamic condition and 
without bloodshed; and patients with various se-
rious cardio respiratory diseases, patients who 
received blood transfusion with Hb values over 
100 g/L and who had stable homodynamic con-
dition counted as unnecessary transfusions (10).
The application of transfusion therapy in patients 
with GIB according to data of some authors (36), 
is made in the average values of hemoglobin 
84 g/L while other authors referred mean val-
ues of Hb 94 g/L before application of TT (37).
Other data from the literature (38), have resulted in 
greater participation of patients (up to 92%), who 
as a criterion for treatment with blood transfusion 
had Hb levels below 70 g/L, compared with our data 
where this participation of the patients was 71.3%.
The data showed by Mathoulin-Pelssier et al, rep-
resented TT in patients with GIB in 175 hospitals 
in France. They found that transfused mean dose 
of blood product was 3.7 per patient. Patients 
with GIB were treated with concentrated eryth-
rocytes (83.4%), FFP (14.8%) and concentrated 
platelet (1.73%) (39). The similar data we found 
in our patients, who were treated with blood 
products: erythrocytes, FFP and concentrated 
platelet (78.6%, 20.8%, and 0.6%) with mean 
transfused dose 3.1 per patient. Data showed 
by other authors (29, 30, 33) found the mean 
transfused dose between 4.8-6.75 per patient. 
The data from UK wide audit of GIB showed in-
appropriate transfusion more common for platelet 
and FFP transfusion than for red blood cells. In 
this study, PT testing was performed in 71% of 
patients with GIB who have received FFP. 27% of 
the tested patients have had normal values of PT 
and INR 1,5 and these are regarded as unneces-
sary transfusions (10). Therefore the application 
of Fresh Frozen Plasma should be used when the 
values of PT are prolonged for 3 seconds and INR 
is under 1,5. PT testing was performed in 43% of 
our patients (61/142) before transfusion treatment 
with Fresh Frozen Plasma, but after that, only 2, 
1% where retested, with minimal and maximal 
value of PT 20% respectively 120%. But Lee et al 
found INR values of PT 2,1 plus SD 0,11 in pa-
tients (68/71) with gastrointestinal bleeding (40). 
Also and data showed by Defreyne Luc et al pre-
sented PT < 50% in 25 % of patients with GIB (41).
Conclusions 
Based on this study it can be concluded that the 
transfusion treatment with blood and blood prod-
ucts is more than necessary for the patients with 
gastrointestinal bleeding. Having in mind diffi-
cult clinical and unsustainable situation of these 
cases the treatment of the patients with gastro-
intestinal bleeding with blood respectively with 
blood products has resulted in the considerable 
improvement of the specific blood indicators. 
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